Evidence map›Paper›PMID 41521159›Full record

ArticleCancer medicine2026

Clinical Significance and Therapeutic Potential of Long Non-Coding RNA H19 in Soft Tissue Sarcoma.

Stephan Jahn, Katarina Krajina, Maria Anna Smolle, Dimyana Neufeldt, Katharina Jonas, Beate Rinner, Kevin Mellert, Maxim Noeparast, Martin Trepel, Joanna Szkandera and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stephan JahnDiagnostic and Research Institute of Pathology, Comprehensive Cancer Center, Subunit Sarcoma, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0002-0330-0274
Katarina KrajinaTranslational Oncology, II. Med Clinics, University of Augsburg, Augsburg, Germany.
Maria Anna SmolleDepartment of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0003-1021-0899
Dimyana NeufeldtTranslational Oncology, II. Med Clinics, University of Augsburg, Augsburg, Germany.
Katharina JonasResearch Unit for Non-Coding RNA and Genome Editing, Division of Oncology, Medical University of Graz, Graz, Austria.
Beate RinnerDivision of Biomedical Research, Medical University of Graz, Graz, Austria.
Kevin MellertInstitute of Pathology, University Hospital Ulm, Ulm, Germany.
Maxim NoeparastTranslational Oncology, II. Med Clinics, University of Augsburg, Augsburg, Germany.ORCID https://orcid.org/0000-0002-3216-5630
Martin TrepelDepartment of Hematology and Medical Oncology, University Medical Center Augsburg, Augsburg, Germany.
Joanna SzkanderaDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Martin PichlerTranslational Oncology, II. Med Clinics, University of Augsburg, Augsburg, Germany.
Bernadette Liegl-AzwangerDiagnostic and Research Institute of Pathology, Comprehensive Cancer Center, Subunit Sarcoma, Medical University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong non-coding RNA (lncRNA) H19 plays a pivotal role in the pathogenesis of different human cancers, but its role in soft tissue sarcoma (STS) has not yet been defined.

methodsWe analyzed H19 expression patterns in various cancer cell lines, focusing on sarcoma subtypes. RNA in situ hybridization was performed on a tissue microarray (n = 150) to assess H19 expression in human STS samples. Univariate and multivariate analyses were conducted to evaluate H19's prognostic value. In STS cell lines with high H19 expression, a Gapmer-based knock-down approach was used to study the functional impact of H19 expression.

resultsLow H19 expression was associated with poor prognosis in univariate analysis (HR: 0.564; 95% CI: 0.324-0.985; p = 0.044). Multivariate analysis showed advanced patient age (p < 0.001) and large tumor size (p = 0.002) as independent predictors of worse overall survival, irrespective of H19 expression (HR: 0.655; 95% CI: 0.367-1.170; p = 0.153). H19 knockdown in STS cell lines reduced cellular growth and increased pro-apoptotic activity. DISCUSSION: Our findings suggest that H19 might play a role in STS pathogenesis. While its prognostic value requires further investigation, H19-based targeting approaches may warrant evaluation for therapeutic potential in STS.

Indexed as

RNA, Long NoncodingSarcomaAdultAgedApoptosisBiomarkers, TumorCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMaleMiddle AgedPrognosisBiomarkers, TumorH19 long non-coding RNARNA, Long NoncodingH19long non‐coding RNAsoft tissue sarcoma

Identifiers

PMID41521159
PMCPMC12790950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.